teclistamab
genmab,janssen
['majestec-1', 'multiplemyeloma', 'janssen']
for us #hcps attending #asco23, see dr. niels van de donk s presentation on the long-term follow-up of the phase 1/2 majestec-1 study evaluating a bcmaxcd3 bispecific antibody in patient with relapsed/refractory #multiplemyeloma. 
Dedicated to sharing Janssen Oncology scientific communications for US HCPs. Account run by Janssen Global Services LLC. Review our Guidelines: https://t.co/uieWByQjn3.